Mitoribosome‐Targeting Antibiotics Suppress Osteoclastogenesis and Periodontitis‐Induced Bone Loss by Blocking Mitochondrial Protein Synthesis
The FASEB Journal · 15.09.2025 · 39 (17)
DOI: 10.1096/fj.202501619r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 09.09.2025. Verfasst von Bulin Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, …. Hauptthemen laut MEDLINE: Periodontitis, Osteoclasts, Anti-Bacterial Agents, Mitochondrial Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation (China Postdoctoral Foundation Project).
Abstract (Originalsprache)
The onset and progression of periodontitis are closely related to metabolic reprogramming in the periodontal microenvironment, with osteoclasts playing a critical role in tissue destruction. Single‐cell RNA sequencing (scRNA‐seq) of periodontal tissues from healthy individuals and patients with severe chronic periodontitis revealed a significant increase in the expression of mitochondrial‐related genes during osteoclast differentiation, suggesting the critical role of mitochondrial function in this process. This study investigates the potential of the novel mitoribosome‐targeting antibiotic radezolid in inhibiting osteoclast differentiation. In vitro experiments showed that radezolid significantly suppressed osteoclast differentiation in RAW264.7 and bone marrow‐derived macrophage (BMM) cells, and further analysis using flow cytometry and electron microscopy confirmed its inhibitory effect on mitochondrial function. Additionally, the addition of pyruvate was able to restore the NAD + /NADH ratio in the cells and partially reversed the inhibitory effects induced by radezolid. Finally, a rat model of periodontitis was used to validate the therapeutic potential of radezolid in inhibiting the progression of periodontitis. Taken together, these results suggest that radezolid, through targeting mitochondrial function, offers a novel therapeutic strategy for periodontitis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cance…
ORCID-Profile: Fuming He
Förderung
- National Natural Science Foundation of China (NSFC)
- China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
Zitieren
APA
Jiang, B., Zeng, Y., Zhu, H., Jiang, J., Cai, F., Yao, H., Jiang, C., & He, F. (2025). Mitoribosome‐Targeting Antibiotics Suppress Osteoclastogenesis and Periodontitis‐Induced Bone Loss by Blocking Mitochondrial Protein Synthesis. The FASEB Journal, 39(17). https://doi.org/10.1096/fj.202501619r
Vancouver
Jiang B, Zeng Y, Zhu H, Jiang J, Cai F, Yao H, et al. Mitoribosome‐Targeting Antibiotics Suppress Osteoclastogenesis and Periodontitis‐Induced Bone Loss by Blocking Mitochondrial Protein Synthesis. The FASEB Journal. 2025;39(17). doi:10.1096/fj.202501619r
BibTeX
@article{Jiang2025,
author = {Jiang, Bulin and Zeng, Yingyu and Zhu, Han and Jiang, Jimin and Cai, Fangyuan and Yao, Hantao and Jiang, Chao and He, Fuming},
title = {Mitoribosome‐Targeting Antibiotics Suppress Osteoclastogenesis and Periodontitis‐Induced Bone Loss by Blocking Mitochondrial Protein Synthesis},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {17},
doi = {10.1096/fj.202501619r}
}
EUVIMED